NASDAQ: ARCT
Arcturus Therapeutics Holdings Inc Stock

$17.93+1.88 (+11.71%)
Updated Feb 5, 2025
ARCT Price
$17.93
Fair Value Price
N/A
Market Cap
$485.68M
52 Week Low
$14.30
52 Week High
$45.00
P/E
-7.66x
P/B
1.85x
P/S
3.92x
PEG
N/A
Dividend Yield
N/A
Revenue
$160.40M
Earnings
-$62.64M
Gross Margin
100%
Operating Margin
-43.18%
Profit Margin
-39.1%
Debt to Equity
0.42
Operating Cash Flow
-$60M
Beta
1.21
Next Earnings
Mar 5, 2025
Ex-Dividend
N/A
Next Dividend
N/A

ARCT Overview

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine ARCT's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

C
Value
C
Growth
D
Momentum
B
Sentiment
D
Safety
C
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
ARCT
Ranked
#41 of 558

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important ARCT news, forecast changes, insider trades & much more!

ARCT News

Overview

Due Diligence Score

Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ARCT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ARCT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ARCT is good value based on its book value relative to its share price (1.85x), compared to the US Biotechnology industry average (5.04x)
P/B vs Industry Valuation
ARCT is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ARCT due diligence checks available for Premium users.

Valuation

ARCT price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-7.66x
Industry
-153.98x
Market
31.5x

ARCT price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
1.85x
Industry
5.04x
ARCT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ARCT's financial health

Profit margin

Revenue
$41.7M
Net Income
-$6.9M
Profit Margin
-16.6%
ARCT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ARCT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$370.7M
Liabilities
$108.8M
Debt to equity
0.42
ARCT's short-term assets ($330.82M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ARCT's short-term assets ($330.82M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ARCT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ARCT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$23.8M
Investing
-$80.0k
Financing
$693.0k
ARCT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ARCT vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
ARCTC$485.68M+11.71%-7.66x1.85x
PROKD$487.08M+5.70%-3.04x-0.50x
UPBC$483.44M+1.69%N/A-3.02x
ANABC$488.68M-2.73%-2.64x5.79x
SVRAD$489.11M-0.35%-6.63x2.45x

Arcturus Therapeutics Holdings Stock FAQ

What is Arcturus Therapeutics Holdings's quote symbol?

(NASDAQ: ARCT) Arcturus Therapeutics Holdings trades on the NASDAQ under the ticker symbol ARCT. Arcturus Therapeutics Holdings stock quotes can also be displayed as NASDAQ: ARCT.

If you're new to stock investing, here's how to buy Arcturus Therapeutics Holdings stock.

What is the 52 week high and low for Arcturus Therapeutics Holdings (NASDAQ: ARCT)?

(NASDAQ: ARCT) Arcturus Therapeutics Holdings's 52-week high was $45.00, and its 52-week low was $14.30. It is currently -60.16% from its 52-week high and 25.38% from its 52-week low.

How much is Arcturus Therapeutics Holdings stock worth today?

(NASDAQ: ARCT) Arcturus Therapeutics Holdings currently has 27,087,359 outstanding shares. With Arcturus Therapeutics Holdings stock trading at $17.93 per share, the total value of Arcturus Therapeutics Holdings stock (market capitalization) is $485.68M.

Arcturus Therapeutics Holdings stock was originally listed at a price of $52.85 in May 22, 2013. If you had invested in Arcturus Therapeutics Holdings stock at $52.85, your return over the last 11 years would have been -66.07%, for an annualized return of -9.36% (not including any dividends or dividend reinvestments).

How much is Arcturus Therapeutics Holdings's stock price per share?

(NASDAQ: ARCT) Arcturus Therapeutics Holdings stock price per share is $17.93 today (as of Feb 5, 2025).

What is Arcturus Therapeutics Holdings's Market Cap?

(NASDAQ: ARCT) Arcturus Therapeutics Holdings's market cap is $485.68M, as of Feb 7, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Arcturus Therapeutics Holdings's market cap is calculated by multiplying ARCT's current stock price of $17.93 by ARCT's total outstanding shares of 27,087,359.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.